FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090845793> ?p ?o ?g. }

• W2090845793 endingPage "819" @default.
• W2090845793 startingPage "814" @default.
• W2090845793 abstract "Background Although the therapeutic outcome of acquired aplastic anemia has improved markedly with the introduction of immunosuppressive therapy using antithymocyte globulin and cyclosporine, a significant proportion of patients subsequently relapse and require second-line therapy. However, detailed analyses of relapses in aplastic anemia children are limited.Design and Methods We previously conducted two prospective multicenter trials of immunosuppressive therapy for children with aplastic anemia: AA-92 and AA-97, which began in 1992 and 1997, respectively. In this study, we assessed the relapse rate, risk factors for relapse, and the response to second-line treatment in children with aplastic anemia treated with antithymocyte globulin and cyclosporine.Results From 1992 to 2007, we treated 441 children with aplastic anemia with standard immunosuppressive therapy. Among the 264 patients who responded to immunosuppressive therapy, 42 (15.9%) relapsed. The cumulative incidence of relapse was 11.9% at 10 years. Multivariate analysis revealed that relapse risk was significantly associated with an immunosuppressive therapy regimen using danazol (relative risk, 3.15; P=0.001) and non-severe aplastic anemia (relative risk, 2.51; P=0.02). Seventeen relapsed patients received additional immunosuppressive therapy with antithymocyte globulin and cyclosporine. Eight patients responded within 6 months. Seven of nine non-responders to second immunosuppressive therapy received hematopoietic stem cell transplantation and five are alive. Eleven patients underwent hematopoietic stem cell transplantation directly and seven are alive.Conclusions In the present study, the cumulative incidence of relapse at 10 years was relatively low compared to that in other studies mainly involving adult patients. A multicenter prospective study is warranted to establish optimal therapy for children with aplastic anemia." @default.
• W2090845793 created "2016-06-24" @default.
• W2090845793 creator A5000663340 @default.
• W2090845793 creator A5006642512 @default.
• W2090845793 creator A5007864049 @default.
• W2090845793 creator A5008274536 @default.
• W2090845793 creator A5010053130 @default.
• W2090845793 creator A5023276521 @default.
• W2090845793 creator A5025014885 @default.
• W2090845793 creator A5030021970 @default.
• W2090845793 creator A5030491895 @default.
• W2090845793 creator A5036837883 @default.
• W2090845793 creator A5046162726 @default.
• W2090845793 creator A5046190031 @default.
• W2090845793 creator A5046860113 @default.
• W2090845793 creator A5060517318 @default.
• W2090845793 creator A5064052373 @default.
• W2090845793 creator A5065982743 @default.
• W2090845793 creator A5066456848 @default.
• W2090845793 creator A5069030165 @default.
• W2090845793 creator A5077700276 @default.
• W2090845793 creator A5084323300 @default.
• W2090845793 date "2011-03-21" @default.
• W2090845793 modified "2023-09-26" @default.
• W2090845793 title "Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group" @default.
• W2090845793 cites W1502200885 @default.
• W2090845793 cites W1517672097 @default.
• W2090845793 cites W1820573680 @default.
• W2090845793 cites W1970679991 @default.
• W2090845793 cites W1970972261 @default.
• W2090845793 cites W1978366547 @default.
• W2090845793 cites W2005518037 @default.
• W2090845793 cites W2011059381 @default.
• W2090845793 cites W2014581521 @default.
• W2090845793 cites W2036245297 @default.
• W2090845793 cites W2037236933 @default.
• W2090845793 cites W2037546451 @default.
• W2090845793 cites W2038981426 @default.
• W2090845793 cites W2047157188 @default.
• W2090845793 cites W2066484486 @default.
• W2090845793 cites W2068866006 @default.
• W2090845793 cites W2071159074 @default.
• W2090845793 cites W2073210769 @default.
• W2090845793 cites W2085418826 @default.
• W2090845793 cites W2107462250 @default.
• W2090845793 cites W2113343307 @default.
• W2090845793 cites W2150570014 @default.
• W2090845793 cites W2153556905 @default.
• W2090845793 cites W2158837255 @default.
• W2090845793 cites W2214497638 @default.
• W2090845793 cites W59852947 @default.
• W2090845793 cites W51958043 @default.
• W2090845793 doi "https://doi.org/10.3324/haematol.2010.035600" @default.
• W2090845793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3105642" @default.
• W2090845793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21422115" @default.
• W2090845793 hasPublicationYear "2011" @default.
• W2090845793 type Work @default.
• W2090845793 sameAs 2090845793 @default.
• W2090845793 citedByCount "28" @default.
• W2090845793 countsByYear W20908457932012 @default.
• W2090845793 countsByYear W20908457932013 @default.
• W2090845793 countsByYear W20908457932014 @default.
• W2090845793 countsByYear W20908457932015 @default.
• W2090845793 countsByYear W20908457932016 @default.
• W2090845793 countsByYear W20908457932017 @default.
• W2090845793 countsByYear W20908457932018 @default.
• W2090845793 countsByYear W20908457932019 @default.
• W2090845793 countsByYear W20908457932020 @default.
• W2090845793 countsByYear W20908457932021 @default.
• W2090845793 crossrefType "journal-article" @default.
• W2090845793 hasAuthorship W2090845793A5000663340 @default.
• W2090845793 hasAuthorship W2090845793A5006642512 @default.
• W2090845793 hasAuthorship W2090845793A5007864049 @default.
• W2090845793 hasAuthorship W2090845793A5008274536 @default.
• W2090845793 hasAuthorship W2090845793A5010053130 @default.
• W2090845793 hasAuthorship W2090845793A5023276521 @default.
• W2090845793 hasAuthorship W2090845793A5025014885 @default.
• W2090845793 hasAuthorship W2090845793A5030021970 @default.
• W2090845793 hasAuthorship W2090845793A5030491895 @default.
• W2090845793 hasAuthorship W2090845793A5036837883 @default.
• W2090845793 hasAuthorship W2090845793A5046162726 @default.
• W2090845793 hasAuthorship W2090845793A5046190031 @default.
• W2090845793 hasAuthorship W2090845793A5046860113 @default.
• W2090845793 hasAuthorship W2090845793A5060517318 @default.
• W2090845793 hasAuthorship W2090845793A5064052373 @default.
• W2090845793 hasAuthorship W2090845793A5065982743 @default.
• W2090845793 hasAuthorship W2090845793A5066456848 @default.
• W2090845793 hasAuthorship W2090845793A5069030165 @default.
• W2090845793 hasAuthorship W2090845793A5077700276 @default.
• W2090845793 hasAuthorship W2090845793A5084323300 @default.
• W2090845793 hasBestOaLocation W20908457931 @default.
• W2090845793 hasConcept C120665830 @default.
• W2090845793 hasConcept C121332964 @default.
• W2090845793 hasConcept C126322002 @default.
• W2090845793 hasConcept C2777408962 @default.
• W2090845793 hasConcept C2778248108 @default.
• W2090845793 hasConcept C2780007613 @default.
• W2090845793 hasConcept C2780252810 @default.

• next